Pharmacogenetic Analysis of Human Steroid 5α Reductase Type II: Comparison of Finasteride and Dutasteride

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The conversation discusses preferences for hair loss treatments, specifically finasteride over dutasteride. Users share personal experiences, cost considerations, FDA approval status, and potential side effects, with some switching between treatments to find what works best for them.

DHT in the scalp, not the bloodstream, is crucial for hair loss. Treatments discussed include finasteride, minoxidil, dutasteride, and microneedling.

Dutasteride might be better for hairline due to varying levels of 5AR activity in scalps. Genetic tests can determine if finasteride is enough or if dutasteride is needed.

The conversation discusses the effectiveness of hair loss treatments, specifically finasteride and dutasteride. The conclusion is that dutasteride significantly reduces DHT levels and may be more effective than finasteride for long-term hair retention, with some users reporting personal experiences and side effects.

Finasteride can impact neurosteroids, potentially causing depression and other side effects in some users. Despite these concerns, many continue using it for hair loss, with some switching to topical applications to mitigate side effects.